Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

mike perry

  • Home
  •  
  • mike perry



  • Most Read
  • Latest Comments
  • Spray-on skin revenue exceeds initial forecasts
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Spray-on skin revenue exceeds initial forecasts
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Spray-on skin revenue exceeds initial forecasts
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Spray-on skin revenue exceeds initial forecasts
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Spray-on skin revenue exceeds initial forecasts
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AVITA Medical to collaborate with Regenity Biosciences to expand their skin regeneration portfolio
    AVITA Medical to collaborate with Regenity Biosciences to expand their skin regeneration portfolio
    • News

  • Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    • News

  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    • News

  • First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    • News

  • Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma
    Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma
    • News

  • Spray-on skin revenue exceeds initial forecasts
    • News

    Spray-on skin revenue exceeds initial forecasts

    The inventors of “spray-on skin”, Avita Medical (ASX: AVH) have today released their financial results for the fiscal fourth quarter with the Company reporting strong revenue. The Company was founded to develop and commercialise the RECELL “spray-on skin” product, invented in Perth by Professor Fiona Wood. Professor Wood is a world renowned surgeon and researcher

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.